Tambocor

(flecainide acetate)

PreclinicalSmall molecule

Tambocor is one of 4 small molecule programs targeting Catecholaminergic Polymorphic Ventricular Tachycardia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Catecholaminergic Polymorphic Ventricular TachycardiaActive, not recruiting

Catecholaminergic Polymorphic Ventricular TachycardiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Catecholaminergic Polymorphic Ventricular Tachycardia

#DrugCompanyPhaseTrials

CRD-4730

CCardurion Pharmaceuticals, Inc.

Phase 2

2 2

Atropen

FFresenius Kabi Taiwan Ltd.

Preclinical

1 3

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 4

Tambocor

AAlvogen Korea

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuropathic Pain1 trial

Flecainide in Treating Patients With Chronic Neuropathic Pain

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00002996·20 enrolled

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

Completed·VVanderbilt University Medical Center·N/A·NCT01117454·14 enrolled

Atrial Fibrillation1 trial

INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

Completed·IInCarda Therapeutics, Inc.·Phase 2·NCT03539302·176 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 23, 1988

TAMBOCOR

NDA NDA018830

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for flecainide acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — flecainide acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for flecainide acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018830). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Alvogen Korea company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAlvogen Korea

Tambocor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuropathic Pain1 trial

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

Atrial Fibrillation1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News